首页> 外文期刊>Journal of healthcare engineering. >Empirical Study on the Transparency of Security Risk Information in Chinese Listed Pharmaceutical Enterprises Based on the ANP-DS Method
【24h】

Empirical Study on the Transparency of Security Risk Information in Chinese Listed Pharmaceutical Enterprises Based on the ANP-DS Method

机译:基于ANP-DS方法的中国上市药品企业安全风险信息透明度的实证研究

获取原文
       

摘要

Frequent outbreaks of drug safety incidents pose a massive threat to public health and safety, while the transparency of security risk information in medical enterprises is not optimistic. Therefore, this study uses the analytic network process (Dempster-Shafer method) to construct a transparent comprehensive evaluation model for security risk information in listed pharmaceutical enterprises from the perspective of government supervision and listed pharmaceutical enterprises. On the basis of 59,305 data obtained by 303 enterprises listed in the Chinese biomedical sector, this research conducted an empirical study on the transparency of safety risk information in Chinese listed pharmaceutical enterprises. The current study found that the transparency of security risk information in Chinese listed pharmaceutical enterprises is generally between general and relatively good and tends to be relatively good. However, administrative punishment information, adverse drug reaction reporting systems, and production processes need continuous improvement.
机译:频繁爆发药物安全事件对公共卫生和安全构成了巨大的威胁,而医疗企业安全风险信息的透明度则并不乐观。因此,本研究采用了分析网络进程(Dempster-Shafer方法)从政府监督和上市制药企业的角度构建列出的制药企业安全风险信息透明综合评价模型。该研究基于303个在中国生物医学部门上市的企业获得的59,305个数据,对中国上市药品企业安全风险信息的透明度进行了实证研究。目前的研究发现,中国上市药品企业安全风险信息的透明度一般在一般和相对良好之间,往往相对较好。但是,行政惩罚信息,不良药物反应报告系统和生产过程需要持续改进。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号